Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label
Chenghai Yang1, Jie Cheng2, Meng Zhang3
1Department of Gastroenterology, Integrative Microecology Clinical Centre, Shenzhen Key Laboratory of Gastrointestinal Microbiota and Disease, Shenzhen Clinical Research Centre for Digestive Disease, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Background:
Bismuth quadruple therapy (BQT) is a recommended first-line regimen for Helicobacter pylori (H. pylori) eradication., but its use is limited by side effects and restricted bismuth availability. Probiotic represents an investigational alternative strategy. This study compared the efficacy and safety of triple therapy plus probiotics (TTP)with BQT.
Methods:
Patients with H. pylori infection were randomised to receive either TTP (probiotics, amoxicillin, clarithromycin and esomeprazole) or BQT (bismuth potassium citrate, amoxicillin, clarithromycin and esomeprazole) for 14 d. The primary endpoint was the eradication rate by 13C-urea breath test ≥28 d after treatment completion. Secondary endpoints included adverse events and adherence.
Results:
The eradication rates for TTP vs. BQT were 76.4% (126/165) and 86.6% (142/164) in the intention-to-treat (ITT) analysis (difference, -10.2%; 95% CI: -18.5% to -1.9%; P = 0.521) and 84.0% (126/150) and 94.7% (142/150) in the protocol (PP) analysis (difference, -10.7%; 95% CI: -17.5% to -3.8%, P = 0.576). Among patients aged ≥40 y, eradication rates were comparable between TTP and BQT in both the ITT and PP analysis (91.9% vs. 84.9% and 97.1% vs. 93.8%, P = 0.015 and P = 0.019 for noninferiority, respectively). The incidence of adverse event was lower in the TTP group (17.8% vs. 28.7%; P = 0.029). Furthermore, TTP preserved gut microbiota stability, whereas BQT induced dysbiosis.
Conclusion:
While TTP was inferior to BQT in eradication efficacy, it demonstrated better tolerability and protective effects against gut microbiota dysbiosis. In patients aged ≥40 y, TTP achieved non-inferior eradication rates, suggesting this subgroup may warrant further investigation.
Trial Registration Number:
ChiCTR2200058491.
More Related Videos
03:47Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
06:12Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors